comparemela.com

Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United Kingdom ,United States ,Dublin ,Ireland ,Cambridge ,Cambridgeshire ,Bedford ,Massachusetts ,American ,Joseph Sullivan ,Edwardm Kaye ,University Of California San Francisco ,Exchange Commission ,Augmentation Of Nuclear Gene Output Is Stoke ,Company Annual Report On Form ,American Epilepsy Society ,Stoke Therapeutics Inc ,Augmentation Of Nuclear Gene Output ,Pediatric Epilepsy Center ,International Epilepsy Congress ,Nasdaq ,Stoke Therapeutics ,Chief Executive Officer ,California San Francisco ,Efficacy Findings ,Combined Analysis ,Key Safety Findings ,Convulsive Seizure Frequency ,After Last Dose ,Efficacy Findings From ,Label Extension Study ,Vineland Adaptive Behavior Scale ,Behavior Rating Inventory ,Executive Function Preschool Version ,Safety Findings ,Suspected Unexpected Serious Adverse Reactions ,Progress Updates ,International Epilepsy Congress September ,Conference Call ,Targeted Augmentation ,Nuclear Gene Output ,Private Securities Litigation Reform Act ,Annual Report ,

comparemela.com © 2020. All Rights Reserved.